The tumour suppressor PTEN is a key negative regulator of the PI3K-Akt pathway, and is frequently either reduced or lost in human tumours. Murine genetic studies have confirmed that reduction of Pten promotes tumourigenesis in multiple organs, and demonstrated dependency of tumour development on the activation of downstream components such as Akt. Insulin-like growth factors (IGFs) act via IGF1R to activate the PI3K-Akt pathway, and are commonly upregulated in cancer. A contextdependent interplay between IGFs and PTEN exists in normal tissue and tumours; increased IGF2 ligand supply induces Pten expression creating an autoregulatory negative feedback loop, whereas complete loss of PTEN may either cooperate with IGF overexpression in tumour promotion, or result in desensitisation to IGF ligand. However, it remains unknown whether neoplasia associated with Pten loss is dependent on upstream IGF ligand supply in vivo. We evaluated this by generation of Pten þ /À mice with differing allelic dosage of Igf2, an imprinted gene encoding the potent embryonic and tumour growth factor Igf2. We show that biallelic Igf2 supply potentiates a previously unreported Pten þ /À placental phenotype and results in strain-dependent cardiac hyperplasia and neonatal lethality. Importantly, we also show that the effects of Pten loss in vivo are modified by Igf2 supply, as lack of Igf2 results in extended survival and delayed tumour development while biallelic supply is associated with reduced lifespan and accelerated neoplasia in females. Furthermore, we demonstrate that reduction of PTEN protein to heterozygote levels in human MCF7 cells is associated with increased proliferation in response to IGF2, and does not result in desensitisation to IGF2 signalling. These data indicate that the effects of Pten loss at heterozygote levels commonly observed in human tumours are modified by Igf2 ligand, and emphasise the importance of the evaluation of upstream pathways in tumours with Pten loss.
Introduction
PTEN is a dual specificity phosphatase that acts as a key negative regulator of the ligand-activated PI3K-Akt pathway (Carracedo and Pandolfi, 2008) . PTEN acts to dephosphorylate phosphatidyl inositol (3,4,5) triphosphate to the diphosphate (4,5), thus reducing activation of Akt. Germline mutations in PTEN cause Cowden syndrome (OMIM 158350), characterised by hamartomas and increased risk of cancer of the breast, thyroid and endometrium, and somatic mutation and epigenetic silencing of PTEN occur at high frequency in sporadic tumours (for example, COSMIC database http:// www.sanger.ac.uk/genetics/CGP/cosmic/). Pten þ /À mice develop hyperplastic and neoplastic change in multiple organs from 3 months of age and typically die at o15 months from tumours or autoimmune disease (Di Cristofano et al., 1998; Podsypanina et al., 1999; Wang et al., 2010) . These phenotypes are potentiated by reduced Pml, Cdkn2a or Tsc2 dosage (Di Cristofano et al., 2001; Ma et al., 2005; Manning, 2005; Trotman et al., 2006) and partially ameliorated by a decrease in downstream components of the PI3K-Akt pathway such as Akt1, Pdk1 and Rictor (Bayascas et al., 2005; Chen et al., 2006; Guertin et al., 2009) . In contrast, upstream Grb2 heterozygosity does not modify Pten þ /À tumour development (Cully et al., 2004) , indicating selective requirement of additional signalling components in Pten þ /À -associated tumourigenesis. Insulin-like growth factor 2 (IGF2) is a potent embryonic growth factor with homology to IGF1 that signals through IGF1R and insulin receptor isoform A to activate the PI3K-Akt and mitogen-activated protein kinase pathways (Foulstone et al., 2005) . The supply of IGF2 ligand is tightly regulated, with one mechanism being genomic imprinting of Igf2 both in human and mouse. Imprinting restricts Igf2 expression to the paternal allele with reciprocal maternal expression of a non-coding RNA (ncRNA) H19 (Bartolomei et al., 1991; DeChiara et al., 1991) . Coordinate expression of Igf2 and H19 on each allele is regulated by a differentially methylated intergenic imprinting control region (ICR) and competition for shared downstream enhancers between the two loci (Bell and Felsenfeld, 2000) . Loss and gain of function of IGF2 contribute to the human growth disorders Silver-Russell (OMIM #180860) and Beckwith-Wiedemann (OMIM #130650) syndromes, respectively. In the mouse, paternal inheritance of an Igf2 null allele (Igf2 Àp ) is associated with approximately 1% wild-type (wt) levels of Igf2 expression and results in foetoplacental growth restriction (60% wt) (DeChiara et al., 1991) . In contrast, maternal inheritance of a 13 kb H19/ICR deletion (H19 Àm ) results in both loss of ncRNA and biallelic Igf2 expression, Igf2 mRNA levels of 127-219% wt and foetal (127%) and placental (140%) overgrowth (Leighton et al., 1995) . Loss of imprinting of IGF2 is common in human cancers (van Roozendaal et al., 1998; Cui et al., 2002) and murine studies have confirmed that Igf2 is required for tumour progression in the RIP-TAg pancreatic (Christofori et al., 1994) , Apc
Min intestinal (Hassan and Howell, 2000) and the Ptch þ /À medulloblastoma models (Corcoran et al., 2008) , whereas biallelic Igf2 supply in combination with Apc
Min promotes adenoma progression (Sakatani et al., 2005; Harper et al., 2006) . Recently, growth regulatory and tumour suppressive roles for H19 have been established (Yoshimizu et al., 2008; Gabory et al., 2009) , and tumour-promoting miRNA (micro RNA) within the Igf2 (miR-483*) and H19 (miR-675-3p) loci reported (Tsang et al., 2010; Veronese et al., 2010) .
As a negative regulator of the PI3K-Akt pathway, PTEN performs a pivotal role in the regulation of IGF2 signalling, and several lines of evidence indicate a complex interplay between IGF2 and PTEN in normal tissues and tumours. Pten expression is induced in response to IGF2 ligand supply, generating negative feedback loops dependent on Egr1 and IGFBP2 (Moorehead et al., 2003; Perks et al., 2007) . Moreover, evidence in human glioblastomas with PTEN loss indicates that IGF2 overexpression promotes tumour growth, suggesting that the two may cooperate in tumour development (Soroceanu et al., 2007) . However, desensitisation of IGF signalling can occur following either PI3 K activation or PTEN loss through feedback mechanisms that include regulation of IGF1R levels, insulin receptor substrate (IRS)-1 stability, regulation of IRS2 and inhibition of IRS-1 by protein kinase C (PKC)z (Liu et al., 2001; Ravichandran et al., 2001; Lackey et al., 2007) . Collectively, these data suggest that although subtle changes in Igf2 and Pten expression may autoregulate through feedback mechanisms, such compensation is inadequate to prevent the effects of allelic dosage variation of either gene in the mouse (DeChiara et al., 1991; Leighton et al., 1995; Di Cristofano et al., 1998; Podsypanina et al., 1999) (Figures 1a and b) . Unexpectedly, we also detected an increase in Pten þ /À foetal and placental weights by E15.5 (119% and 123% wt, respectively, Po0.001 both comparisons) that subsequently diminished in the foetus by E18.5 (107% wt, P ¼ NS) but persisted in the placenta (122% wt, Po0.001). H19
Àm , Pten þ /À compound mutants were, in turn, larger than either class of single mutant (Figures 1a  and b) , though the combination was less than additive in the foetus (131% wt at E15.5 and E18.5) and greater than additive in the placenta (165% and 180% wt, Po0.001 vs all groups) (Figures 1a and b ).
An approximate doubling of Igf2 mRNA in H19
Àm
and H19 Àm , Pten þ /À mutant placentas was associated with a relatively smaller increase in protein (Figure 1c , Supplementary Figures S1a and b) , whereas Pten expression and protein in Pten heterozygotes were half and two thirds wt level, respectively, and independent of Igf2 ( Figure 1d , Supplementary Figures S1c and d) . As expected, the decrease in Pten protein was accompanied by an increase in Ser473-phosphorylated Akt (p-Akt S473 ) in both Pten þ /À and H19 Àm , Pten þ /À mutants (Figure 1d ), though importantly, no additional effect of biallelic Igf2 expression was detected on Akt and Erk 1/ 2 activation. We next evaluated localisation of the placental growth effects. The murine placenta can be divided into three zones; the part-maternally derived decidua; the junctional zone, comprising spongiotrophoblast (Sp) and glycogen cells (Gly); and the labyrinth (Lab), which contains foetal and maternal vessels and is the site of nutrient exchange. Overgrowth of H19 Àm placentas was largely associated with preservation of placental architecture, whereas Pten þ /À mutants displayed tortuosity of the Sp/Lab interface by E15.5 with expansion of the junctional zone (31.48 ± 1.7 vs 25.7±1.68% in wt) (Figures 1e and f) .
Biallelic Igf2 supply potentiated both Pten þ /À placental phenotypes, with marked abnormality of the Sp/Lab border and greater increase in the size of the junctional zone (34.8 ± 3.49%, Po0.05 vs wt) in H19 (Figures 1e and f) . Gly cells are known to be Igf2 dependent (Lopez et al., 1996; Carter et al., 2006; Esquiliano et al., 2009) and, as anticipated, were present in increased numbers at E18.5 in H19
Àm placentas, Figure S1g) .
We next generated mice with varying allelic dosage of Igf2: null (Igf2 Àp ), monoallelic or biallelic expression and either wt or heterozygous Pten supply on a uniform F1 hybrid C57BL/6/129S2 background. This both reproduced the growth effects and confirmed that the Pten þ /À foetoplacental phenotype persisted despite near complete absence of Igf2 (Supplementary Figures S2a-c) .
Biallelic Igf2 supply combined with Pten þ /À results in cardiac hyperplasia and neonatal lethality By postnatal day 10 on a C57BL/6 background, a deficit of H19

,Pten
þ /À compound mutants was evident (49% of expected, Po0.0001). This was greater in females than males (29% of expected, Po0.001 vs 64%, P ¼ NS) (Supplementary Figure S3a) . A significant and disproportionate increase in heart weights in H19 Figure S3c) . Collectively, these data suggested an association between the cardiac abnormalities and lethality. Quantification of cardiomyocyte density demonstrated growth because of hyperplasia (Supplementary Figure S3f) , and analysis confirmed expected Igf2 and Pten mRNA and protein levels in mutant hearts (not shown). As cardiac abnormalities may result from placental defects, we re-examined H19 Àm ,Pten þ /À placentas by sex, but found no differences between males and females (not shown (Figures 2a-c) . This was largely because of effects in females where these differences were greater (373 days, 305.5 days and 274.5 days, respectively, P ¼ 0.0008 and Po0.0001), and a significant decrease in survival with biallelic vs monoallelic Igf2 expression was also observed (Figure 2c ). Lifespan of males was longer as anticipated (Manning, 2005) , and did not vary significantly between groups (Figure 2b) Figures S4a-c) . Furthermore, histopathological analysis demonstrated a tendency to higher-grade lymphoid lesions with Igf2 gain of function (Supplementary figures S4d-g).
We next focused on the effects of variation of Igf2 allelic supply on epithelial gene expression and tumourigenesis. RT-qPCR (reverse transcriptase-quantitative PCR) on mammary glands, endometria and prostates of virgin animals of 6-8-weeks age confirmed that although Igf2 expression was reduced to approximately 1% of the levels of E9.5 embryos, it remained detectable and was substantially reduced in Igf2
Àp mutants (1-8% wt), and doubled in H19
Àm mutants (178.9-200% wt) (Supplementary Figures S5a-c) . H19 expression was greatly reduced in H19
Àm mutants, though no significant change was found in tissues from Igf2
Àp animals and no alteration in Pten expression with change in Igf2 supply was detected ( Supplementary  Figures S5d-f) .
Clinically detectable mammary carcinomas in females occurred significantly later in Igf2 Àp ,Pten þ /À mutants than both Pten þ /À and H19 Àm ,Pten þ /À groups. These data were combined with systematic analysis of macroscopically normal female mammary glands (see Supplementary methods) to determine the true incidence and timing of mammary neoplasia. A trend towards fewer carcinomas in Igf2
Àp
,Pten
þ /À mutants ( Figure 3a ) was accompanied by a significant delay in tumour onset (Figure 3b ). Carcinomas were histologically similar in all cohorts with prominent stromal component (Figure 3c) , with no differences in proliferation by ki67 labelling (not shown). No metastases were detected in any group. No pathological changes were observed in Pten wt female (n ¼ 6) or Pten (Figure 4a) . Conversely, tumour multiplicity tended to increase with gain of Igf2 alleles (Figure 4b ). Mammary hyperplasia, a preneoplastic lesion (Supplementary Figure S6a) , was detected at similar frequency in females of all genotypes (Figure 3a) , suggesting that Igf2 may promote the transition to carcinoma in Pten þ /À females. RT-qPCR confirmed that Igf2 expression in mammary carcinomas corresponded with Igf2 allelic dose ( Figure 4c) . As in the normal mammary gland, H19 expression was substantially decreased in H19 Àm ,Pten þ /À mutant carcinomas (Supplementary Figure S6b) . Levels of Pten mRNA in tumours relative to wt mammary gland were reduced by a similar degree in all genotypes (P ¼ NS) (Figure 4d ). There was no evidence of feedback downregulation of Igf1r secondary to this (Supplementary Figure S6c) , though interestingly Igf1 Figure 6g) . Immunohistochemistry demonstrated foci of epithelial Pten loss in a minority of advanced lesions only (Figure 4g ), insufficient in extent to fully explain the relative reduction in total protein.
Perturbation of miR-483* and miR-675-3p in Igf2
Àp and H19 Àm mutants Given the recent demonstration of tumour-promoting functions for miR-483 and miR-675, we next assessed whether their perturbation in Igf2
Àp and H19 (Figures 5a and b) . We next examined changes in miRNA expression in both classes of mutant using Ilumina 96-assay universal array matrix miRNA arrays.
miR-483* is located within the second intron of Igf2 in a region of the gene spared by the targeting construct used in this study (DeChiara et al., 1990) . We anticipated an increase in miR-483* levels in H19 Àm mutants of similar magnitude to that of Igf2, but surprisingly this was not the case (105.1% wt, P ¼ NS). Also unexpected was an upregulation of miR-483* in Igf2
Àp mutants (107.3% wt) (Figure 5c ). Importantly, no correlation between Igf2 and miR-483* expression was detected (R 2 ¼ 0.365, P ¼ NS). miR-675-3p is located within the first exon of H19, which is deleted along with (Leighton et al., 1995) . As expected, H19
Àm mutants showed a significant decrease in miR-675-3p expression (78.1% wt, Po0.001), though this was smaller than the reduction in H19 ncRNA (Figure 5d) . Notably, miR-675-3p expression was unchanged in Igf2
Àp mutants (99.6% wt, P ¼ NS) (Figure 5d ). Changes in the expression of 377 additional miRNAs analysed were modest and are listed in Supplementary Table S1 . Aside from miRNA perturbations that we could attribute to expression of the neomycin resistance gene, we observed a number of Igf2 dependent Pten þ /À phenotypes DN Church et al miRNAs deregulated to similar extents in mutants as miR-483* and miR-675-3p. Importantly, no miRNA significantly downregulated in Igf2
Àp embryos demonstrated significant upregulation in H19
Àm embryos, or vice versa.
Reduction of PTEN protein to heterozygote levels in human breast cancer cells associated with increased IGF2-mediated proliferation PTEN loss has previously been shown to cause desensitisation to IGF1 and insulin signalling (Lackey et al., 2007) . To reconcile these results with our data, and to examine the interaction between IGF2 and PTEN loss in a system free from H19 ncRNA, miR-483* and miR-675-3p perturbation, we used shRNA (small hairpin RNA) to reduce PTEN expression to heterozygote levels in MCF7 human breast cancer cells. 
) and Erk1/2 (p-Erk T202/204 ) (Figure 6a ). It has also been shown in MCF7 cells that high concentrations of IGF2 result in relative inhibition of cellular proliferation through feedback induction of PTEN (Perks et al., 2007) . We next assessed whether partial PTEN knockdown abrogated this autoregulation. Stimulation of MCF7 CTRL and MCF7 PTEN KD cells with increasing concentrations of IGF2 confirmed the mitogenic effect of recombinant ligand at concentrations of >1 ng/ml, and as anticipated in MCF7 CTRL cells this plateaued at 100 ng/ml (Figure 6c) . Notably, MCF7 PTEN KD cells demonstrated increased proliferation in response to IGF2, most strikingly at high ligand concentrations, with no evidence of a plateau in proliferation (Figure 6c ).
Human stromal interaction of IGF2 and PTEN Finally, in light of the apparent promotion of stromapredominant Pten þ /À mammary tumours by Igf2 in the mouse, we evaluated the expression of IGF2 and PTEN in human breast carcinomas. We analysed two microarray data sets with normal and tumour samples, the first comprising a cohort of whole breast tumours (Camps et al., 2008) and the second a published breast cancer micro-dissected stroma data set (Finak et al., 2008) . In whole tumours, IGF2 overexpression was relatively infrequent with a >2-fold increase in mRNA detected in 5.6% of tumours (Figure 7a ). Unlike the mouse mutants, miR-483 expression closely correlated with that of IGF2 (R 2 ¼ 0.6, Po2.2 Â 10
À16
) and was in fact reduced in tumours compared with normal breast (88.9%, Po2.44 Â 10
À13
), whereas miR-675 expression was not significantly altered (98.6%, P ¼ NS). Interestingly, the decrease in PTEN expression in breast tumours was modest (median 89.1% normal breast), with few tumours showing levels o50% of normal breast (Figure 7b ). In contrast, stromal-specific analysis demonstrated near-universal increase in IGF2 (median 176%, P ¼ 0.0012) and decrease in PTEN expression (median 11.1%, P ¼ 1.87 Â 10 À5 ) in tumour stroma compared with normal stroma (Figures 7c and d) .
Discussion
We sought to determine whether variation in Igf2 supply secondary to change in Igf2 allelic dosage modifies Pten þ /À tumourigesis in order to evaluate the extent to which the effects of Pten loss in vivo are dependent upon upstream signalling. We report several novel findings with respect to development and tumourigenesis.
The Pten þ /À placental phenotype we describe demonstrates tissue-specific requirements for biallelic Pten expression in mammalian development. Although both Pten þ /À placental overgrowth and Sp disorganisation were increased by biallelic Igf2 supply, they were not ameliorated in Igf2 null mutants, and the discrete localisation of Igf2, Pten and p-Akt S473 within the placental Lab are consistent with a complex interaction (Coan et al., 2006) . However, when combined with the Akt1 null placental phenotype of small size, Sp and Gly cell deficiency (Yang et al., 2003) Although placental abnormalities in mouse mutants are frequently more severe on a C57BL/6 background, we confirmed that this is strain independent (Frank et al., 2002) . We failed to detect quantitative differences in proliferation to explain the placental overgrowth in mid-gestation, and it is plausible that our findings result either from subtle cumulative changes or variation earlier than E12.5 (Burns and Hassan, 2001 ). The use of conditional Igf2 and Pten alleles may facilitate mechanistic insights into the relationship between upstream Igf2 expression and localisation and Pten loss in the placenta.
It is noteworthy that similar to the placenta, Igf2 is expressed at high levels in neonatal heart, and recent data suggest an important role for Igf2 in cardiac development (Li et al., 2011) . Though conditional deletion of both Pten alleles results in cardiac hypertrophy (Crackower, 2002) , murine cardiac effects of germline heterozygosity have to the best of our knowledge not previously been described. However, a case of ventricular dilatation has been reported in the human (Reardon et al., 2001) . The cardiac hyperplasia and neonatal lethality with combined Igf2 and Pten dysregulation we report is consistent with an interaction in heart development, though confirmation of this will require the use of conditional genetics to exclude placental effects.
Igf2 has previously been shown to function as a progression factor or second signal in tumour development (Christofori et al., 1994; Hassan and Howell, 2000; Harper et al., 2006; Corcoran et al., 2008) . We demonstrate that the marked reduction of Igf2 expression (1-8% wt) in Igf2
Àp and more modest increase (179-200% wt) in H19
Àm mutants are associated with respectively a substantial amelioration and lesser potentiation of Pten þ /À tumourigenesis, consistent with a similar role for Igf2 in the context of Pten haploinsufficiency. It is noteworthy that these changes occurred at relevant levels of Igf2 expression, in contrast to previous transgenic non-physiological studies (Bates et al., 1995) . Pten þ /À mammary tumours typically retain heterozygote levels of Pten protein (Alimonti et al., 2010) . The progressive decrease in tumour Pten protein with gain of Igf2 is suggestive of additional posttranscriptional regulatory mechanisms, and contrasts with the previous report of Pten upregulation in response to increased Igf2 (Moorehead et al., 2003) . With respect to other relevant feedback regulation secondary to PTEN loss, such as desensitisation to IGF (Lackey et al., 2007) , decreased Pten protein in mammary carcinomas was not accompanied by downregulation of Igf1r expression. Moreover, reduction of PTEN to heterozygote levels in MCF7 human breast cancer cells resulted in potentiation of the mitogenic effects of IGF2. These changes were greatest at high doses of ligand, consistent with abrogation of the feedback mechanism of PTEN upregulation previously demonstrated (Moorehead et al., 2003; Perks et al., 2007) . Collectively, these data suggest that the effects generated by heterozygote levels of PTEN may still be dependent on upstream ligand.
As noted previously, the H19 ncRNA has recently been demonstrated to have tumour suppressive activity in vivo (Yoshimizu et al., 2008) , whereas miRNAs in the IGF2 and H19 loci; miR-483 and miR-675 respectively, have both been ascribed tumour-promoting effects (Tsang et al., 2010; Veronese et al., 2010) . Although Igf2 expression across the allelic series increased from 1 to 247%, there was no similar variation of any miRNA. Importantly, loss of H19 (o1% of wt) was not mirrored by equivalent reduction in miR-675-3p in H19 Àm mutants, and miR-483* expression appeared relatively unchanged. Disruption of miR-483* and miR-675-3p was minimal in Igf2
Àp animals, with no consistent pattern of H19 dysregulation detected. In addition to these changes, our global analysis shows that many independent miRNA are deregulated in both Igf2
Àp and H19 Àm mutants. Our data cannot exclude selective dysregulation of miR-483* and miR-675-3p in tumours, as the small number of Igf2
Àp
,Pten
þ /À tumours available precluded meaningful analysis. Definitive in vivo assessment of the contribution of the miR-483* and miR-675-3p to phenotype may only be provided by specific conditional deletion of respective loci that modify miRNA expression independent of Igf2. However, our in vitro data demonstrate the proliferative effects of IGF2 at heterozygote levels of PTEN protein in a system free from H19, miR-483* and miR-675-3p perturbation.
IGF2 overexpression by human breast cancer stroma has been postulated to promote neoplastic growth by a paracrine mechanism (Singer et al., 1995) . We demonstrate that increased Igf2 mRNA in stroma-prominent Pten þ /À murine mammary tumours is mirrored by nearuniversal upregulation of IGF2 and downregulation of PTEN in human breast cancer stroma. The role of stromal Pten in suppression of mammary tumourigenesis has recently been demonstrated (Trimboli et al., 2009) . Our data suggest that the role of stromal IGF2 in breast cancers merits further examination.
In summary, we show that variation of Igf2 ligand supply is associated with modification of development, survival and tumourigenesis in Pten þ /À mice, that these changes are unlikely to result from perturbation of the H19 ncRNA, miR-483* or miR-675-3p, and that IGF2 ligand cooperates with partial PTEN loss to promote breast cancer cell proliferation in vitro. Collectively, these data indicate that the effects of Pten loss at heterozygote levels commonly observed in human tumours are modified by Igf2, and emphasise the importance of the evaluation of upstream pathways in tumours with Pten loss. 
Materials and methods
Mice
